IP Library Granted Patent US 9,127,277
Granted Patent B2
US 9,127,277 · App. 13/778,614 · Granted Sep 8, 2015

Methods and compositions for prevention or treatment of RSV infection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,127,277
App. No.
13/778,614
Granted
Sep 8, 2015
Kind
B2
Abstract

Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets.

Claims (1175)

1. A method of reducing the risk of Respiratory Syncytial Virus (RSV) associated bronchiolitis obliterans syndrome (BOS) in a subject, comprising administering to said subject a composition comprising a therapeutically effective amount of a dsRNA that targets a P, N, or L gene of RSV wherein the dsRNA comprises a sense strand and an antisense strand and each strand is 15-30 nucleotides in length, wherein the antisense strand of the dsRNA targeting the N gene is complementary to at least 15 contiguous nucleotides of SEQ ID NOS: 277-284.

2. The method of claim 1 , wherein the sense strand is selected from SEQ ID NOs: 3-116, 231-249, and 269-276, and the antisense strand is selected from SEQ ID NOs: 117-230, 250-268, and 277-284.

3. The method of claim 1 , wherein said subject is a human lung transplant recipient.

4. The method of claim 1 , wherein said subject is receiving bronchodilator therapy.

5. The method of claim 1 , wherein ribavarin is administered to said subject.

6. The method of claim 1 , wherein said administration is intranasal or intrapulmonary.

7. The method of claim 6 , wherein said intrapulmonary administration is by inhalation of said composition.

8. The method of claim 1 , wherein said composition is administered as an aerosol.

9. The method of claim 8 , wherein said aerosol is a nasal spray.

10. The method of claim 8 , wherein said aerosol is produced by a nebulizer.

11. The method of claim 10 , wherein said nebulizer is a PARI eFlow® 30L nebulizer.

12. The method of claim 1 , comprising administering a plurality of doses of said composition.

13. The method of claim 12 , wherein one of said plurality of doses is administered daily.

14. The method of claim 12 , wherein said plurality of doses is two or three doses.

15. The method of claim 12 , wherein said subject is presently infected with RSV when the first of said plurality of doses is administered.

16. The method of claim 12 , wherein said administering of said plurality of doses is by inhalation and delivers a total dose of between 0.1 and 0.6 mg/kg of anhydrous oligonucleotide to said subject.

17. The method of claim 1 , further comprising determining a characteristic of RSV infection, wherein said characteristic is selected from RSV mRNA, RSV peak viral load, time to peak RSV viral load, duration of RSV viral shedding, RSV viral AUC, or RSV titer.

18. The method of claim 1 , wherein said administering reduces RSV protein, RSV mRNA, RSV peak viral load, time to peak RSV viral load, duration of RSV viral shedding, RSV viral AUC, or RSV titer in a cell of the respiratory tract of said subject.

19. The method of claim 1 , wherein said administration of said composition to said subject is started within seven days of onset of symptoms of RSV infection, wherein said symptoms comprise a decrease in FEV1, fever, new onset rhinorrhea, sore throat, nasal congestion, cough, wheezing, headache, myalgia, chills, or shortness of breath.

20. The method of claim 1 , wherein said administration of said composition improves FEV1 or causes a reduction in one or more symptoms of RSV infection in said subject relative to a placebo, wherein said symptoms are selected from the group consisting of fever, new onset rhinorrhea, sore throat, nasal congestion, cough, wheezing, headache, myalgia, chills, or shortness of breath or prevents a reduction in lung function for at least 90 days as determined by measurement of a FEV1 in said subject.

21. The method of claim 17 , wherein said characteristic of RSV infection is determined by quantitative RT-PCR (qRT-PCR) analysis of a nasal swab sample and/or a sputum sample from said subject.

22. The method of claim 4 , wherein said human lung transplant recipient is administered said composition within one hour of receiving bronchodilator therapy.

23. The method of claim 5 , wherein said subject is administered said composition one to two hours before administration of ribavirin.

24. The method of claim 1 , wherein the method prevents a reduction in lung function for at least 90 days as determined by measurement of a FEV1 in the lung transplant recipient.

25. The method of claim 1 , wherein the dsRNA comprises one of the following sense strand and antisense strand pairs:

SEQ ID

SEQ ID

NO.

Sense

NO.

Antisense

  3

GGAUCCCAUUAUUAAUGGAdTdT

117

UCCAUUAAUAAUGGGAUCCdTdT

  4

GAUCCCAUUAUUAAUGGAAdTdT

118

UUCCAUUAAUAAUGGGAUCdTdT

  5

AGUUAUUUAAAAGGUGUUAdTdT

119

UAACACCUUUUAAAUAACUdTdT

  6

GUUAUUUAAAAGGUGUUAUdTdT

120

AUAACACCUUUUAAAUAACdTdT

  7

AUUUAAAAGGUGUUAUCUCdTdT

121

GAGAUAACACCUUUUAAAUdTdT

  8

UUAAAAGGUGUUAUCUCUUdTdT

122

AAGAGAUAACACCUUUUAAdTdT

  9

AAGUCCACUACUAGAGCAUdTdT

123

AUGCUCUAGUAGUGGACUUdTdT

 10

AGUCCACUACUAGAGCAUAdTdT

124

UAUGCUCUAGUAGUGGACUdTdT

 11

GUCCACUACUAGAGCAUAUdTdT

125

AUAUGCUCUAGUAGUGGACdTdT

 12

UCCACUACUAGAGCAUAUGdTdT

126

CAUAUGCUCUAGUAGUGGAdTdT

 13

GAAGAGCUAUAGAAAUAAGdTdT

127

CUUAUUUCUAUAGCUCUUCdTdT

 14

GAGCUAUAGAAAUAAGUGAdTdT

128

UCACUUAUUUCUAUAGCUCdTdT

 15

CUAUAGAAAUAAGUGAUGUdTdT

129

ACAUCACUUAUUUCUAUAGdTdT

 16

UCAAAACAACACUCUUGAAdTdT

130

UUCAAGAGUGUUGUUUUGAdTdT

 17

UAGAGGGAUUUAUUAUGUCdTdT

131

GACAUAAUAAAUCCCUCUAdTdT

 18

AUAAAAGGGUUUGUAAAUAdTdT

132

UAUUUACAAACCCUUUUAUdTdT

 19

CUCAGUGUAGGUAGAAUGUdTdT

133

ACAUUCUACCUACACUGAGdTdT

 20

UCAGUGUAGGUAGAAUGUUdTdT

134

AACAUUCUACCUACACUGAdTdT

 21

CAGUGUAGGUAGAAUGUUUdTdT

135

AAACAUUCUACCUACACUGdTdT

 22

AGUGUAGGUAGAAUGUUUGdTdT

136

CAAACAUUCUACCUACACUdTdT

 23

GUGUAGGUAGAAUGUUUGCdTdT

137

GCAAACAUUCUACCUACACdTdT

 24

ACAAGAUAUGGUGAUCUAGdTdT

138

CUAGAUCACCAUAUCUUGUdTdT

 25

AGCAAAUUCAAUCAAGCAUdTdT

139

AUGCUUGAUUGAAUUUGCUdTdT

 26

GCAAAUUCAAUCAAGCAUUdTdT

140

AAUGCUUGAUUGAAUUUGCdTdT

 27

GAUGAACAAAGUGGAUUAUdTdT

141

AUAAUCCACUUUGUUCAUCdTdT

 28

UAAUAUCUCUCAAAGGGAAdTdT

142

UUCCCUUUGAGAGAUAUUAdTdT

 29

AUAUCUCUCAAAGGGAAAUdTdT

143

AUUUCCCUUUGAGAGAUAUdTdT

 30

UAUCUCUCAAAGGGAAAUUdTdT

144

AAUUUCCCUUUGAGAGAUAdTdT

 31

CAUGCUCAAGCAGAUUAUUdTdT

145

AAUAAUCUGCUUGAGCAUGdTdT

 32

UGCUCAAGCAGAUUAUUUGdTdT

146

CAAAUAAUCUGCUUGAGCAdTdT

 33

UAGCAUUAAAUAGCCUUAAdTdT

147

UUAAGGCUAUUUAAUGCUAdTdT

 34

AGCAUUAAAUAGCCUUAAAdTdT

148

UUUAAGGCUAUUUAAUGCUdTdT

 35

GCAUUAAAUAGCCUUAAAUdTdT

149

AUUUAAGGCUAUUUAAUGCdTdT

 36

CAUUAAAUAGCCUUAAAUUdTdT

150

AAUUUAAGGCUAUUUAAUGdTdT

 37

UAUUAUGCAGUUUAAUAUUdTdT

151

AAUAUUAAACUGCAUAAUAdTdT

 38

UUAUGCAGUUUAAUAUUUAdTdT

152

UAAAUAUUAAACUGCAUAAdTdT

 39

AAAAGUGCACAACAUUAUAdTdT

153

UAUAAUGUUGUGCACUUUUdTdT

 40

AAAGUGCACAACAUUAUACdTdT

154

GUAUAAUGUUGUGCACUUUdTdT

 41

AUAUAGAACCUACAUAUCCdTdT

155

GGAUAUGUAGGUUCUAUAUdTdT

 42

UAUAGAACCUACAUAUCCUdTdT

156

AGGAUAUGUAGGUUCUAUAdTdT

 43

UAAGAGUUGUUUAUGAAAGdTdT

157

CUUUCAUAAACAACUCUUAdTdT

 44

ACAGUCAGUAGUAGACCAUdTdT

158

AUGGUCUACUACUGACUGUdTdT

 45

CAGUCAGUAGUAGACCAUGdTdT

159

CAUGGUCUACUACUGACUGdTdT

 46

AGUCAGUAGUAGACCAUGUdTdT

160

ACAUGGUCUACUACUGACUdTdT

 47

GUCAGUAGUAGACCAUGUGdTdT

161

CACAUGGUCUACUACUGACdTdT

 48

UCAGUAGUAGACCAUGUGAdTdT

162

UCACAUGGUCUACUACUGAdTdT

 49

CAUGUGAAUUCCCUGCAUCdTdT

163

GAUGCAGGGAAUUCACAUGdTdT

 50

AUGUGAAUUCCCUGCAUCAdTdT

164

UGAUGCAGGGAAUUCACAUdTdT

 51

UGUGAAUUCCCUGCAUCAAdTdT

165

UUGAUGCAGGGAAUUCACAdTdT

 52

GUGAAUUCCCUGCAUCAAUdTdT

166

AUUGAUGCAGGGAAUUCACdTdT

 53

AAUUCCCUGCAUCAAUACCdTdT

167

GGUAUUGAUGCAGGGAAUUdTdT

 54

GCAUCAAUACCAGCUUAUAdTdT

168

UAUAAGCUGGUAUUGAUGCdTdT

 55

CAUCAAUACCAGCUUAUAGdTdT

169

CUAUAAGCUGGUAUUGAUGdTdT

 56

AUACCAGCUUAUAGAACAAdTdT

170

UUGUUCUAUAAGCUGGUAUdTdT

 57

UACCAGCUUAUAGAACAACdTdT

171

GUUGUUCUAUAAGCUGGUAdTdT

 58

ACCAGCUUAUAGAACAACAdTdT

172

UGUUGUUCUAUAAGCUGGUdTdT

 59

CCAGCUUAUAGAACAACAAdTdT

173

UUGUUGUUCUAUAAGCUGGdTdT

 60

CAGCUUAUAGAACAACAAAdTdT

174

UUUGUUGUUCUAUAAGCUGdTdT

 61

AUAGAACAACAAAUUAUCAdTdT

175

UGAUAAUUUGUUGUUCUAUdTdT

 62

UAUUAACAGAAAAGUAUGGdTdT

176

CCAUACUUUUCUGUUAAUAdTdT

 63

UGAGAUACAUUUGAUGAAAdTdT

177

UUUCAUCAAAUGUAUCUCAdTdT

 64

GAGAUACAUUUGAUGAAACdTdT

178

GUUUCAUCAAAUGUAUCUCdTdT

 65

GAUACAUUUGAUGAAACCUdTdT

179

AGGUUUCAUCAAAUGUAUCdTdT

 66

AUACAUUUGAUGAAACCUCdTdT

180

GAGGUUUCAUCAAAUGUAUdTdT

 67

UACAUUUGAUGAAACCUCCdTdT

181

GGAGGUUUCAUCAAAUGUAdTdT

 68

AAGUGAUACAAAAACAGCAdTdT

182

UGCUGUUUUUGUAUCACUUdTdT

 69

AGUGAUACAAAAACAGCAUdTdT

183

AUGCUGUUUUUGUAUCACUdTdT

 70

UGAUACAAAAACAGCAUAUdTdT

184

AUAUGCUGUUUUUGUAUCAdTdT

 71

UUUAAGUACUAAUUUAGCUdTdT

185

AGCUAAAUUAGUACUUAAAdTdT

 72

UUAAGUACUAAUUUAGCUGdTdT

186

CAGCUAAAUUAGUACUUAAdTdT

 73

UAAGUACUAAUUUAGCUGGdTdT

187

CCAGCUAAAUUAGUACUUAdTdT

 74

AAGUACUAAUUUAGCUGGAdTdT

188

UCCAGCUAAAUUAGUACUUdTdT

 75

AGUACUAAUUUAGCUGGACdTdT

189

GUCCAGCUAAAUUAGUACUdTdT

 76

GUACUAAUUUAGCUGGACAdTdT

190

UGUCCAGCUAAAUUAGUACdTdT

 77

ACUAAUUUAGCUGGACAUUdTdT

191

AAUGUCCAGCUAAAUUAGUdTdT

 78

AAUUUAGCUGGACAUUGGAdTdT

192

UCCAAUGUCCAGCUAAAUUdTdT

 79

AUUUAGCUGGACAUUGGAUdTdT

193

AUCCAAUGUCCAGCUAAAUdTdT

 80

UUAGCUGGACAUUGGAUUCdTdT

194

GAAUCCAAUGUCCAGCUAAdTdT

 81

UUUUGAAAAAGAUUGGGGAdTdT

195

UCCCCAAUCUUUUUCAAAAdTdT

 82

UUUGAAAAAGAUUGGGGAGdTdT

196

CUCCCCAAUCUUUUUCAAAdTdT

 83

UGAAAAAGAUUGGGGAGAGdTdT

197

CUCUCCCCAAUCUUUUUCAdTdT

 84

GAAAAAGAUUGGGGAGAGGdTdT

198

CCUCUCCCCAAUCUUUUUCdTdT

 85

UAUGAACACUUCAGAUCUUdTdT

199

AAGAUCUGAAGUGUUCAUAdTdT

 86

AUGAACACUUCAGAUCUUCdTdT

200

GAAGAUCUGAAGUGUUCAUdTdT

 87

UGCCCUUGGGUUGUUAACAdTdT

201

UGUUAACAACCCAAGGGCAdTdT

 88

GCCCUUGGGUUGUUAACAUdTdT

202

AUGUUAACAACCCAAGGGCdTdT

 89

UAUAGCAUUCAUAGGUGAAdTdT

203

UUCACCUAUGAAUGCUAUAdTdT

 90

AUAGCAUUCAUAGGUGAAGdTdT

204

CUUCACCUAUGAAUGCUAUdTdT

 91

UAGCAUUCAUAGGUGAAGGdTdT

205

CCUUCACCUAUGAAUGCUAdTdT

 92

AUUCAUAGGUGAAGGAGCAdTdT

206

UGCUCCUUCACCUAUGAAUdTdT

 93

UUGCAAUGAUCAUAGUUUAdTdT

207

UAAACUAUGAUCAUUGCAAdTdT

 94

UGCAAUGAUCAUAGUUUACdTdT

208

GUAAACUAUGAUCAUUGCAdTdT

 95

GCAAUGAUCAUAGUUUACCdTdT

209

GGUAAACUAUGAUCAUUGCdTdT

 96

CAAUGAUCAUAGUUUACCUdTdT

210

AGGUAAACUAUGAUCAUUGdTdT

 97

AAUGAUCAUAGUUUACCUAdTdT

211

UAGGUAAACUAUGAUCAUUdTdT

 98

AUGAUCAUAGUUUACCUAUdTdT

212

AUAGGUAAACUAUGAUCAUdTdT

 99

GAUCAUAGUUUACCUAUUGdTdT

213

CAAUAGGUAAACUAUGAUCdTdT

100

AUCAUAGUUUACCUAUUGAdTdT

214

UCAAUAGGUAAACUAUGAUdTdT

101

UCAUAGUUUACCUAUUGAGdTdT

215

CUCAAUAGGUAAACUAUGAdTdT

102

CAUAGUUUACCUAUUGAGUdTdT

216

ACUCAAUAGGUAAACUAUGdTdT

103

AUAGUUUACCUAUUGAGUUdTdT

217

AACUCAAUAGGUAAACUAUdTdT

104

CAUUGGUCUUAUUUACAUAdTdT

218

UAUGUAAAUAAGACCAAUGdTdT

105

UUGGUCUUAUUUACAUAUAdTdT

219

UAUAUGUAAAUAAGACCAAdTdT

106

UGGUCUUAUUUACAUAUAAdTdT

220

UUAUAUGUAAAUAAGACCAdTdT

107

GGUCUUAUUUACAUAUAAAdTdT

221

UUUAUAUGUAAAUAAGACCdTdT

108

AUAUCAUGCUCAAGAUGAUdTdT

222

AUCAUCUUGAGCAUGAUAUdTdT

109

UAUCAUGCUCAAGAUGAUAdTdT

223

UAUCAUCUUGAGCAUGAUAdTdT

110

UGAUAUUGAUUUCAAAUUAdTdT

224

UAAUUUGAAAUCAAUAUCAdTdT

111

UACUUAGUCCUUACAAUAGdTdT

225

CUAUUGUAAGGACUAAGUAdTdT

112

UUAGUCCUUACAAUAGGUCdTdT

226

GACCUAUUGUAAGGACUAAdTdT

113

UAGUCCUUACAAUAGGUCCdTdT

227

GGACCUAUUGUAAGGACUAdTdT

114

AUAUUCUAUAGCUGGACGUdTdT

228

ACGUCCAGCUAUAGAAUAUdTdT

115

UAUUCUAUAGCUGGACGUAdTdT

229

UACGUCCAGCUAUAGAAUAdTdT

116

AUUCUAUAGCUGGACGUAAdTdT

230

UUACGUCCAGCUAUAGAAUdTdT

231

AAAUUCCUAGAAUCAAUAAdTdT

250

UUAUUGAUUCUAGGAAUUUdTdT

232

AAUUCCUAGAAUCAAUAAAdTdT

251

UUUAUUGAUUCUAGGAAUUdTdT

233

UUCCUAGAAUCAAUAAAGGdTdT

252

CCUUUAUUGAUUCUAGGAAdTdT

234

UCCUAGAAUCAAUAAAGGGdTdT

253

CCCUUUAUUGAUUCUAGGAdTdT

235

CUAGAAUCAAUAAAGGGCAdTdT

254

UGCCCUUUAUUGAUUCUAGdTdT

236

ACAUUUGAUAACAAUGAAGdTdT

255

CUUCAUUGUUAUCAAAUGUdTdT

237

CAUUUGAUAACAAUGAAGAdTdT

256

UCUUCAUUGUUAUCAAAUGdTdT

238

AUUUGAUAACAAUGAAGAAdTdT

257

UUCUUCAUUGUUAUCAAAUdTdT

239

UUUGAUAACAAUGAAGAAGdTdT

258

CUUCUUCAUUGUUAUCAAAdTdT

240

AAGUGAAAUACUAGGAAUGdTdT

259

CAUUCCUAGUAUUUCACUUdTdT

241

AGUGAAAUACUAGGAAUGCdTdT

260

GCAUUCCUAGUAUUUCACUdTdT

242

GUGAAAUACUAGGAAUGCUdTdT

261

AGCAUUCCUAGUAUUUCACdTdT

243

UGAAAUACUAGGAAUGCUUdTdT

262

AAGCAUUCCUAGUAUUUCAdTdT

244

GAAAUACUAGGAAUGCUUCdTdT

263

GAAGCAUUCCUAGUAUUUCdTdT

245

AAAUACUAGGAAUGCUUCAdTdT

264

UGAAGCAUUCCUAGUAUUUdTdT

246

GAAGCAUUAAUGACCAAUGdTdT

265

CAUUGGUCAUUAAUGCUUCdTdT

247

AAGCAUUAAUGACCAAUGAdTdT

266

UCAUUGGUCAUUAAUGCUUdTdT

248

CGAUAAUAUAACAGCAAGAdTsdT

267

UCUUGCUGUUAUAUUAUCGdTsdT

249

CGAUUAUAUUACAGGAUGAdTsdT

268

UCAUCCUGUAAUAUAAUCGdTsdT

  1

GGCUCUUAGCAAAGUCAAGdTdT

  2

CUUGACUUUGCUAAGAGCCdTdT

269

CUCUUAGCAAAGUCAAGUUdTdT

277

AACUUGACUUUGCUAAGAGdTdT

270

CUGUCAUCCAGCAAAUACAdTdT

278

UGUAUUUGCUGGAUGACAGdTdT

271

UGUCAUCCAGCAAAUACACdTdT

279

GUGUAUUUGCUGGAUGACAdTdT

272

UAAUAGGUAUGUUAUAUGCdTdT

280

GCAUAUAACAUACCUAUUAdTdT

273

AUUGAGAUAGAAUCUAGAAdTdT

281

UUCUAGAUUCUAUCUCAAUdTdT

274

AUUCUACCAUAUAUUGAACdTdT

282

GUUCAAUAUAUGGUAGAAUdTdT

275

UUCUACCAUAUAUUGAACAdTdT

283

UGUUCAAUAUAUGGUAGAAdTdT

276

UCUACCAUAUAUUGAACAAdTdT

284

UUGUUCAAUAUAUGGUAGAdTdT.

26. A method of reducing the risk of Respiratory Syncytial Virus (RSV) associated bronchiolitis obliterans syndrome (BOS) in a human lung transplant recipient, comprising administering to said subject a composition comprising a therapeutically effective amount of a dsRNA that targets a P, N, or L gene of RSV wherein the dsRNA comprises a sense strand and an antisense strand and each strand is 15-30 nucleotides in length, wherein the antisense strand of the dsRNA targeting the N gene is complementary to at least 15 contiguous nucleotides of SEQ ID NOS: 277-284, wherein ribavirin is administered to said human lung transplant recipient, and wherein the composition is administered daily as an aerosol produced by a PARI eFlow® 30L nebulizer.

27. A method of reducing the risk of Respiratory Syncytial Virus (RSV) associated bronchiolitis obliterans syndrome (BOS) in a human lung transplant recipient, comprising administering to said subject a composition comprising a therapeutically effective amount of a dsRNA that targets a P, N, or L gene of RSV wherein the dsRNA comprises a sense strand and an antisense strand and each strand is 15-30 nucleotides in length, wherein ribavirin is administered to said human lung transplant recipient, wherein the composition is administered daily as an aerosol produced by a PARI eFlow® 30L nebulizer, and wherein the dsRNA comprises one of the following sense strand and antisense strand pairs:

SEQ ID

SEQ ID

NO.

Sense

NO.

Antisense

  3

GGAUCCCAUUAUUAAUGGAdTdT

117

UCCAUUAAUAAUGGGAUCCdTdT

  4

GAUCCCAUUAUUAAUGGAAdTdT

118

UUCCAUUAAUAAUGGGAUCdTdT

  5

AGUUAUUUAAAAGGUGUUAdTdT

119

UAACACCUUUUAAAUAACUdTdT

  6

GUUAUUUAAAAGGUGUUAUdTdT

120

AUAACACCUUUUAAAUAACdTdT

  7

AUUUAAAAGGUGUUAUCUCdTdT

121

GAGAUAACACCUUUUAAAUdTdT

  8

UUAAAAGGUGUUAUCUCUUdTdT

122

AAGAGAUAACACCUUUUAAdTdT

  9

AAGUCCACUACUAGAGCAUdTdT

123

AUGCUCUAGUAGUGGACUUdTdT

 10

AGUCCACUACUAGAGCAUAdTdT

124

UAUGCUCUAGUAGUGGACUdTdT

 11

GUCCACUACUAGAGCAUAUdTdT

125

AUAUGCUCUAGUAGUGGACdTdT

 12

UCCACUACUAGAGCAUAUGdTdT

126

CAUAUGCUCUAGUAGUGGAdTdT

 13

GAAGAGCUAUAGAAAUAAGdTdT

127

CUUAUUUCUAUAGCUCUUCdTdT

 14

GAGCUAUAGAAAUAAGUGAdTdT

128

UCACUUAUUUCUAUAGCUCdTdT

 15

CUAUAGAAAUAAGUGAUGUdTdT

129

ACAUCACUUAUUUCUAUAGdTdT

 16

UCAAAACAACACUCUUGAAdTdT

130

UUCAAGAGUGUUGUUUUGAdTdT

 17

UAGAGGGAUUUAUUAUGUCdTdT

131

GACAUAAUAAAUCCCUCUAdTdT

 18

AUAAAAGGGUUUGUAAAUAdTdT

132

UAUUUACAAACCCUUUUAUdTdT

 19

CUCAGUGUAGGUAGAAUGUdTdT

133

ACAUUCUACCUACACUGAGdTdT

 20

UCAGUGUAGGUAGAAUGUUdTdT

134

AACAUUCUACCUACACUGAdTdT

 21

CAGUGUAGGUAGAAUGUUUdTdT

135

AAACAUUCUACCUACACUGdTdT

 22

AGUGUAGGUAGAAUGUUUGdTdT

136

CAAACAUUCUACCUACACUdTdT

 23

GUGUAGGUAGAAUGUUUGCdTdT

137

GCAAACAUUCUACCUACACdTdT

 24

ACAAGAUAUGGUGAUCUAGdTdT

138

CUAGAUCACCAUAUCUUGUdTdT

 25

AGCAAAUUCAAUCAAGCAUdTdT

139

AUGCUUGAUUGAAUUUGCUdTdT

 26

GCAAAUUCAAUCAAGCAUUdTdT

140

AAUGCUUGAUUGAAUUUGCdTdT

 27

GAUGAACAAAGUGGAUUAUdTdT

141

AUAAUCCACUUUGUUCAUCdTdT

 28

UAAUAUCUCUCAAAGGGAAdTdT

142

UUCCCUUUGAGAGAUAUUAdTdT

 29

AUAUCUCUCAAAGGGAAAUdTdT

143

AUUUCCCUUUGAGAGAUAUdTdT

 30

UAUCUCUCAAAGGGAAAUUdTdT

144

AAUUUCCCUUUGAGAGAUAdTdT

 31

CAUGCUCAAGCAGAUUAUUdTdT

145

AAUAAUCUGCUUGAGCAUGdTdT

 32

UGCUCAAGCAGAUUAUUUGdTdT

146

CAAAUAAUCUGCUUGAGCAdTdT

 33

UAGCAUUAAAUAGCCUUAAdTdT

147

UUAAGGCUAUUUAAUGCUAdTdT

 34

AGCAUUAAAUAGCCUUAAAdTdT

148

UUUAAGGCUAUUUAAUGCUdTdT

 35

GCAUUAAAUAGCCUUAAAUdTdT

149

AUUUAAGGCUAUUUAAUGCdTdT

 36

CAUUAAAUAGCCUUAAAUUdTdT

150

AAUUUAAGGCUAUUUAAUGdTdT

 37

UAUUAUGCAGUUUAAUAUUdTdT

151

AAUAUUAAACUGCAUAAUAdTdT

 38

UUAUGCAGUUUAAUAUUUAdTdT

152

UAAAUAUUAAACUGCAUAAdTdT

 39

AAAAGUGCACAACAUUAUAdTdT

153

UAUAAUGUUGUGCACUUUUdTdT

 40

AAAGUGCACAACAUUAUACdTdT

154

GUAUAAUGUUGUGCACUUUdTdT

 41

AUAUAGAACCUACAUAUCCdTdT

155

GGAUAUGUAGGUUCUAUAUdTdT

 42

UAUAGAACCUACAUAUCCUdTdT

156

AGGAUAUGUAGGUUCUAUAdTdT

 43

UAAGAGUUGUUUAUGAAAGdTdT

157

CUUUCAUAAACAACUCUUAdTdT

 44

ACAGUCAGUAGUAGACCAUdTdT

158

AUGGUCUACUACUGACUGUdTdT

 45

CAGUCAGUAGUAGACCAUGdTdT

159

CAUGGUCUACUACUGACUGdTdT

 46

AGUCAGUAGUAGACCAUGUdTdT

160

ACAUGGUCUACUACUGACUdTdT

 47

GUCAGUAGUAGACCAUGUGdTdT

161

CACAUGGUCUACUACUGACdTdT

 48

UCAGUAGUAGACCAUGUGAdTdT

162

UCACAUGGUCUACUACUGAdTdT

 49

CAUGUGAAUUCCCUGCAUCdTdT

163

GAUGCAGGGAAUUCACAUGdTdT

 50

AUGUGAAUUCCCUGCAUCAdTdT

164

UGAUGCAGGGAAUUCACAUdTdT

 51

UGUGAAUUCCCUGCAUCAAdTdT

165

UUGAUGCAGGGAAUUCACAdTdT

 52

GUGAAUUCCCUGCAUCAAUdTdT

166

AUUGAUGCAGGGAAUUCACdTdT

 53

AAUUCCCUGCAUCAAUACCdTdT

167

GGUAUUGAUGCAGGGAAUUdTdT

 54

GCAUCAAUACCAGCUUAUAdTdT

168

UAUAAGCUGGUAUUGAUGCdTdT

 55

CAUCAAUACCAGCUUAUAGdTdT

169

CUAUAAGCUGGUAUUGAUGdTdT

 56

AUACCAGCUUAUAGAACAAdTdT

170

UUGUUCUAUAAGCUGGUAUdTdT

 57

UACCAGCUUAUAGAACAACdTdT

171

GUUGUUCUAUAAGCUGGUAdTdT

 58

ACCAGCUUAUAGAACAACAdTdT

172

UGUUGUUCUAUAAGCUGGUdTdT

 59

CCAGCUUAUAGAACAACAAdTdT

173

UUGUUGUUCUAUAAGCUGGdTdT

 60

CAGCUUAUAGAACAACAAAdTdT

174

UUUGUUGUUCUAUAAGCUGdTdT

 61

AUAGAACAACAAAUUAUCAdTdT

175

UGAUAAUUUGUUGUUCUAUdTdT

 62

UAUUAACAGAAAAGUAUGGdTdT

176

CCAUACUUUUCUGUUAAUAdTdT

 63

UGAGAUACAUUUGAUGAAAdTdT

177

UUUCAUCAAAUGUAUCUCAdTdT

 64

GAGAUACAUUUGAUGAAACdTdT

178

GUUUCAUCAAAUGUAUCUCdTdT

 65

GAUACAUUUGAUGAAACCUdTdT

179

AGGUUUCAUCAAAUGUAUCdTdT

 66

AUACAUUUGAUGAAACCUCdTdT

180

GAGGUUUCAUCAAAUGUAUdTdT

 67

UACAUUUGAUGAAACCUCCdTdT

181

GGAGGUUUCAUCAAAUGUAdTdT

 68

AAGUGAUACAAAAACAGCAdTdT

182

UGCUGUUUUUGUAUCACUUdTdT

 69

AGUGAUACAAAAACAGCAUdTdT

183

AUGCUGUUUUUGUAUCACUdTdT

 70

UGAUACAAAAACAGCAUAUdTdT

184

AUAUGCUGUUUUUGUAUCAdTdT

 71

UUUAAGUACUAAUUUAGCUdTdT

185

AGCUAAAUUAGUACUUAAAdTdT

 72

UUAAGUACUAAUUUAGCUGdTdT

186

CAGCUAAAUUAGUACUUAAdTdT

 73

UAAGUACUAAUUUAGCUGGdTdT

187

CCAGCUAAAUUAGUACUUAdTdT

 74

AAGUACUAAUUUAGCUGGAdTdT

188

UCCAGCUAAAUUAGUACUUdTdT

 75

AGUACUAAUUUAGCUGGACdTdT

189

GUCCAGCUAAAUUAGUACUdTdT

 76

GUACUAAUUUAGCUGGACAdTdT

190

UGUCCAGCUAAAUUAGUACdTdT

 77

ACUAAUUUAGCUGGACAUUdTdT

191

AAUGUCCAGCUAAAUUAGUdTdT

 78

AAUUUAGCUGGACAUUGGAdTdT

192

UCCAAUGUCCAGCUAAAUUdTdT

 79

AUUUAGCUGGACAUUGGAUdTdT

193

AUCCAAUGUCCAGCUAAAUdTdT

 80

UUAGCUGGACAUUGGAUUCdTdT

194

GAAUCCAAUGUCCAGCUAAdTdT

 81

UUUUGAAAAAGAUUGGGGAdTdT

195

UCCCCAAUCUUUUUCAAAAdTdT

 82

UUUGAAAAAGAUUGGGGAGdTdT

196

CUCCCCAAUCUUUUUCAAAdTdT

 83

UGAAAAAGAUUGGGGAGAGdTdT

197

CUCUCCCCAAUCUUUUUCAdTdT

 84

GAAAAAGAUUGGGGAGAGGdTdT

198

CCUCUCCCCAAUCUUUUUCdTdT

 85

UAUGAACACUUCAGAUCUUdTdT

199

AAGAUCUGAAGUGUUCAUAdTdT

 86

AUGAACACUUCAGAUCUUCdTdT

200

GAAGAUCUGAAGUGUUCAUdTdT

 87

UGCCCUUGGGUUGUUAACAdTdT

201

UGUUAACAACCCAAGGGCAdTdT

 88

GCCCUUGGGUUGUUAACAUdTdT

202

AUGUUAACAACCCAAGGGCdTdT

 89

UAUAGCAUUCAUAGGUGAAdTdT

203

UUCACCUAUGAAUGCUAUAdTdT

 90

AUAGCAUUCAUAGGUGAAGdTdT

204

CUUCACCUAUGAAUGCUAUdTdT

 91

UAGCAUUCAUAGGUGAAGGdTdT

205

CCUUCACCUAUGAAUGCUAdTdT

 92

AUUCAUAGGUGAAGGAGCAdTdT

206

UGCUCCUUCACCUAUGAAUdTdT

 93

UUGCAAUGAUCAUAGUUUAdTdT

207

UAAACUAUGAUCAUUGCAAdTdT

 94

UGCAAUGAUCAUAGUUUACdTdT

208

GUAAACUAUGAUCAUUGCAdTdT

 95

GCAAUGAUCAUAGUUUACCdTdT

209

GGUAAACUAUGAUCAUUGCdTdT

 96

CAAUGAUCAUAGUUUACCUdTdT

210

AGGUAAACUAUGAUCAUUGdTdT

 97

AAUGAUCAUAGUUUACCUAdTdT

211

UAGGUAAACUAUGAUCAUUdTdT

 98

AUGAUCAUAGUUUACCUAUdTdT

212

AUAGGUAAACUAUGAUCAUdTdT

 99

GAUCAUAGUUUACCUAUUGdTdT

213

CAAUAGGUAAACUAUGAUCdTdT

100

AUCAUAGUUUACCUAUUGAdTdT

214

UCAAUAGGUAAACUAUGAUdTdT

101

UCAUAGUUUACCUAUUGAGdTdT

215

CUCAAUAGGUAAACUAUGAdTdT

102

CAUAGUUUACCUAUUGAGUdTdT

216

ACUCAAUAGGUAAACUAUGdTdT

103

AUAGUUUACCUAUUGAGUUdTdT

217

AACUCAAUAGGUAAACUAUdTdT

104

CAUUGGUCUUAUUUACAUAdTdT

218

UAUGUAAAUAAGACCAAUGdTdT

105

UUGGUCUUAUUUACAUAUAdTdT

219

UAUAUGUAAAUAAGACCAAdTdT

106

UGGUCUUAUUUACAUAUAAdTdT

220

UUAUAUGUAAAUAAGACCAdTdT

107

GGUCUUAUUUACAUAUAAAdTdT

221

UUUAUAUGUAAAUAAGACCdTdT

108

AUAUCAUGCUCAAGAUGAUdTdT

222

AUCAUCUUGAGCAUGAUAUdTdT

109

UAUCAUGCUCAAGAUGAUAdTdT

223

UAUCAUCUUGAGCAUGAUAdTdT

110

UGAUAUUGAUUUCAAAUUAdTdT

224

UAAUUUGAAAUCAAUAUCAdTdT

111

UACUUAGUCCUUACAAUAGdTdT

225

CUAUUGUAAGGACUAAGUAdTdT

112

UUAGUCCUUACAAUAGGUCdTdT

226

GACCUAUUGUAAGGACUAAdTdT

113

UAGUCCUUACAAUAGGUCCdTdT

227

GGACCUAUUGUAAGGACUAdTdT

114

AUAUUCUAUAGCUGGACGUdTdT

228

ACGUCCAGCUAUAGAAUAUdTdT

115

UAUUCUAUAGCUGGACGUAdTdT

229

UACGUCCAGCUAUAGAAUAdTdT

116

AUUCUAUAGCUGGACGUAAdTdT

230

UUACGUCCAGCUAUAGAAUdTdT

231

AAAUUCCUAGAAUCAAUAAdTdT

250

UUAUUGAUUCUAGGAAUUUdTdT

232

AAUUCCUAGAAUCAAUAAAdTdT

251

UUUAUUGAUUCUAGGAAUUdTdT

233

UUCCUAGAAUCAAUAAAGGdTdT

252

CCUUUAUUGAUUCUAGGAAdTdT

234

UCCUAGAAUCAAUAAAGGGdTdT

253

CCCUUUAUUGAUUCUAGGAdTdT

235

CUAGAAUCAAUAAAGGGCAdTdT

254

UGCCCUUUAUUGAUUCUAGdTdT

236

ACAUUUGAUAACAAUGAAGdTdT

255

CUUCAUUGUUAUCAAAUGUdTdT

237

CAUUUGAUAACAAUGAAGAdTdT

256

UCUUCAUUGUUAUCAAAUGdTdT

238

AUUUGAUAACAAUGAAGAAdTdT

257

UUCUUCAUUGUUAUCAAAUdTdT

239

UUUGAUAACAAUGAAGAAGdTdT

258

CUUCUUCAUUGUUAUCAAAdTdT

240

AAGUGAAAUACUAGGAAUGdTdT

259

CAUUCCUAGUAUUUCACUUdTdT

241

AGUGAAAUACUAGGAAUGCdTdT

260

GCAUUCCUAGUAUUUCACUdTdT

242

GUGAAAUACUAGGAAUGCUdTdT

261

AGCAUUCCUAGUAUUUCACdTdT

243

UGAAAUACUAGGAAUGCUUdTdT

262

AAGCAUUCCUAGUAUUUCAdTdT

244

GAAAUACUAGGAAUGCUUCdTdT

263

GAAGCAUUCCUAGUAUUUCdTdT

245

AAAUACUAGGAAUGCUUCAdTdT

264

UGAAGCAUUCCUAGUAUUUdTdT

246

GAAGCAUUAAUGACCAAUGdTdT

265

CAUUGGUCAUUAAUGCUUCdTdT

247

AAGCAUUAAUGACCAAUGAdTdT

266

UCAUUGGUCAUUAAUGCUUdTdT

248

CGAUAAUAUAACAGCAAGAdTsdT

267

UCUUGCUGUUAUAUUAUCGdTsdT

249

CGAUUAUAUUACAGGAUGAdTsdT

268

UCAUCCUGUAAUAUAAUCGdTsdT

  1

GGCUCUUAGCAAAGUCAAGdTdT

  2

CUUGACUUUGCUAAGAGCCdTdT

269

CUCUUAGCAAAGUCAAGUUdTdT

277

AACUUGACUUUGCUAAGAGdTdT

270

CUGUCAUCCAGCAAAUACAdTdT

278

UGUAUUUGCUGGAUGACAGdTdT

271

UGUCAUCCAGCAAAUACACdTdT

279

GUGUAUUUGCUGGAUGACAdTdT

272

UAAUAGGUAUGUUAUAUGCdTdT

280

GCAUAUAACAUACCUAUUAdTdT

273

AUUGAGAUAGAAUCUAGAAdTdT

281

UUCUAGAUUCUAUCUCAAUdTdT

274

AUUCUACCAUAUAUUGAACdTdT

282

GUUCAAUAUAUGGUAGAAUdTdT

275

UUCUACCAUAUAUUGAACAdTdT

283

UGUUCAAUAUAUGGUAGAAdTdT

276

UCUACCAUAUAUUGAACAAdTdT

284

UUGUUCAAUAUAUGGUAGAdTdT.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: VAISHNAW, AKSHAY; NOCHUR, SARASWATHY V.; ELBASHIR, SAYDA; MANOHARAN, MUTHIAH; MEYERS, RACHEL
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 031141/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2013
From: VAISHNAW, AKSHAY; NOCHUR, SARASWATHY V.; ELBASHIR, SAYDA; MANOHARAN, MUTHIAH; MEYERS, RACHEL
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 031062/0035 →